Connolly 2019 - Glucose dysregulation in pre-clinical AD.pdf (234.3 kB)

Glucose dysregulation in pre-clinical Alzheimer's disease.

Download (234.3 kB)
journal contribution
posted on 19.01.2021, 12:01 by Niamh Connolly, Pierre Theurey, Paola Pizzo
AD is the most common cause of age-related dementia and is consistently accompanied by glucose hypo-metabolism that precedes the onset of clinical symptoms, providing potential for early diagnosis and novel therapeutic interventions. Innovative inter-disciplinary research utilising appropriate pre-clinical models is required to further elucidate the molecular mechanisms, cross-talk with Aβ and tau pathology, and translatable approaches targeted to the early stages of AD. Given that glucose hypo‑metabolism has also been measured in other neurodegenerative diseases, we are excited to watch this field progress.

Funding

CeBioND EU Joint Programme for Neurodegenerative Disease Research

History

Comments

The original article is available at https://www.aging-us.com/

Published Citation

Connolly NMC, Theurey P, Pizzo P. Glucose dysregulation in pre-clinical Alzheimer's disease. Aging (Albany NY). 2019;11(15):5296-5297.

Publication Date

4 August 2019

PubMed ID

31386625

Department/Unit

  • Centre for Systems Medicine
  • Physiology and Medical Physics

Research Area

  • Neurological and Psychiatric Disorders

Publisher

Impact Journals, LLC

Version

  • Published Version (Version of Record)

Licence

Exports

Royal College of Surgeons in Ireland

Categories

Licence

Exports